FOLH1 and prostate carcinoma: During robotic prostate cancer surgery using IS-002 (prostate-specific membrane antigen (PSMA)-targeted peptide-based fluorescent tracer), eight out of fourteen LNMs were detected in vivo, resulting in a sensitivity of 57.1% [38].